A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 891-897

  Arnoletti, J P ^a   Frolov, A ^a   Eloubeidi, M ^b   Keene, K ^c   Posey, J ^d   Wood, T ^d   Greeno, Edward ^e   Jhala, N ^f   Varadarajulu, S ^b   Russo, S ^g   Christein, J ^a   Oster, R ^d   Buchsbaum, D J ^c   Vickers, S M ^e  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f University of Alabama at Birmingham   (United States)

^g EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cetuximab; Gemcitabine; Pancreatic cancer; Radiation therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; UVOMORULIN; VIMENTIN;

ABDOMINAL RADIOTHERAPY; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CELL; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; ENDOSCOPIC ECHOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERKALEMIA; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; LOCALLY ADVANCED PANCREATIC CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, FINE-NEEDLE; CADHERINS; COHORT STUDIES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; VIMENTIN;

EID: 79954451282     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1383-0     Document Type: Article

References (34)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. DB Evans TA Rich DR Byrd, et al. 1991 Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease South Med J 84 566 570 2035074 1:STN:280:DyaK3M3ktVemug%3D%3D
3. CG Willett BG Czito JC Bendell, et al. 2005 Locally advanced pancreatic cancer J Clin Oncol 23 4538 4544 16002845 10.1200/JCO.2005.23.911 (Pubitemid 46196584)
4. L Coia J Hoffman R Scher, et al. 1994 Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum Int J Radiat Oncol Biol Phys 30 161 167 8083109 1:STN:280:DyaK2czmsVyksA%3D%3D (Pubitemid 24291126)
5. J Carmichael U Fink RC Russell, et al. 1996 Phase II study of gemcitabine in patients with advanced pancreatic cancer Br J Cancer 73 101 105 8554969 10.1038/bjc.1996.18 1:CAS:528:DyaK28Xht12iurc%3D (Pubitemid 26026268)
6. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
7. JP Hoffman S Lipsitz T Pisansky, et al. 1998 Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study J Clin Oncol 16 317 323 9440759 1:CAS:528:DyaK1cXmsFeqsg%3D%3D (Pubitemid 28041615)
8. CJ McGinn TS Lawrence MM Zalupski 2002 On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer Cancer 95 933 940 12209674 10.1002/cncr.10754 1:CAS:528:DC%2BD38XmsFaqtr8%3D (Pubitemid 34839689)
9. MA Morgan LA Parsels LE Kollar, et al. 2008 The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer Clin Cancer Res 14 5142 5149 18698032 10.1158/1078-0432.CCR-07-4072 1:CAS:528:DC%2BD1cXpslKgtbo%3D
10. H Friess L Wang Z Zhu, et al. 1999 Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas Ann Surg 230 767 774 10615931 10.1097/00000658-199912000-00005 1:STN:280: DC%2BD3c%2FotFKktQ%3D%3D discussion 774-775 (Pubitemid 30191811)
11. HQ Xiong A Rosenberg A LoBuglio, et al. 2004 Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial J Clin Oncol 22 2610 2616 15226328 10.1200/JCO.2004.12.040 1:CAS:528: DC%2BD2cXpsVWksLY%3D (Pubitemid 41103748)
12. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D (Pubitemid 46972777)
13. J Mendelsohn J Baselga 2006 Epidermal growth factor receptor targeting in cancer Semin Oncol 33 369 385 16890793 10.1053/j.seminoncol.2006.04.003 1:CAS:528:DC%2BD28XpsVersLk%3D (Pubitemid 44142736)
14. Liu L, Cao Y, Tan A, Liao C, Gao F (2010) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 65(5):849-861
15. JJ Caudell SM Sawrie SA Spencer, et al. 2008 Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment Int J Radiat Oncol Biol Phys 71 676 681 18355979 10.1016/j.ijrobp.2007.10.040 1:CAS:528:DC%2BD1cXmsFOjur0%3D
16. DJ Buchsbaum JA Bonner WE Grizzle, et al. 2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation Int J Radiat Oncol Biol Phys 54 1180 1193 12419447 10.1016/S0360-3016(02)03788-4 1:CAS:528:DC%2BD38Xotl2lsrg%3D (Pubitemid 35292632)
17. S Thomson E Buck F Petti, et al. 2005 Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 9455 9462 16230409 10.1158/0008-5472.CAN-05-1058 1:CAS:528:DC%2BD2MXhtFWmu73E (Pubitemid 41508014)
18. E Batlle E Sancho C Franci, et al. 2000 The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells Nat Cell Biol 2 84 89 10655587 10.1038/35000034 1:CAS:528:DC%2BD3cXhtVyltLo%3D
19. M Tempero JP Arnoletti E Ben-Josef, et al. 2007 Pancreatic adenocarcinoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 5 998 1033 18053426
20. MP Callery KJ Chang EK Fishman, et al. 2009 Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement Ann Surg Oncol 16 1727 1733 19396496 10.1245/s10434-009-0408-6
21. S Cascinu R Berardi R Labianca, et al. 2008 Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial Lancet Oncol 9 39 44 18077217 10.1016/S1470-2045(07)70383-2 1:CAS:528: DC%2BD1cXivVOlsA%3D%3D
22. F Robert MP Ezekiel SA Spencer, et al. 2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 3234 3243 11432891 1:CAS:528:DC%2BD3MXltlShtb8%3D (Pubitemid 32591441)
23. JA Bonner PM Harari J Giralt, et al. 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 578 16467544 10.1056/NEJMoa053422 1:CAS:528:DC%2BD28Xhtleksbs%3D (Pubitemid 43209104)
24. F Kullmann S Hollerbach MM Dollinger, et al. 2009 Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study Br J Cancer 100 1032 1036 19293797 10.1038/sj.bjc.6604983 1:CAS:528:DC%2BD1MXktVGksbs%3D
25. PA Philip J Benedetti C Fenoglio-Preiser M Zalupski H Lenz E O'Reilly R Wong J Atkins J Abbruzzese C Blanke 2007 Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study J Clin Oncol 25 LBA4509 10.1200/JCO.2006.09.6040 (Pubitemid 46596777)
26. AB Chakravarthy JD Berlin AC Lockhart, et al. 2008 A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 72 S250 S251
27. A Demols C Mahin R Marechal, et al. 2008 Cetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcinoma: a phase I study J Clin Oncol 26 15S 4629
28. M Munter C Timke A Abdollahi, et al. 2008 Final results of a phase II trial (PARC-Study ISRCTN56652283) for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine J Clin Oncol 26 15S 4613
29. W Small J Berlin GM Freedman, et al. 2008 Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial J Clin Oncol 26 942 947 18281668 10.1200/JCO.2007.13.9014 1:CAS:528:DC%2BD1cXjtFelt74%3D (Pubitemid 351398088)
30. DA Eberhard BE Johnson LC Amler, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900 5909 16043828 10.1200/JCO.2005.02.857 1:CAS:528:DC%2BD2MXhtVKgtbzO
31. S Benvenuti A Sartore-Bianchi F Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648 17363584 10.1158/0008-5472.CAN-06-4158 1:CAS:528:DC%2BD2sXivV2ns7w%3D (Pubitemid 46548951)
32. CW Tzeng A Frolov N Frolova, et al. 2007 Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer Surgery 141 464 469 17383523 10.1016/j.surg.2006.09.009 (Pubitemid 46441307)
33. J Yang SA Mani RA Weinberg 2006 Exploring a new twist on tumor metastasis Cancer Res 66 4549 4552 16651402 10.1158/0008-5472.CAN-05-3850 1:CAS:528:DC%2BD28XjvF2ks7Y%3D
34. E Buck A Eyzaguirre S Barr, et al. 2007 Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition Mol Cancer Ther 6 532 541 17308052 10.1158/1535-7163.MCT-06-0462 1:CAS:528:DC%2BD2sXhvVWrsrY%3D (Pubitemid 46332455)